Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC: VYYRF) announced the appointment of Virginia Alling as an independent director, subject to regulatory approval, further strengthening its board with Wall Street expertise to support U.S. market expansion. Alling joins recent board enhancements with Jeffrey J. Kraws and Christopher A. Van Buren, positioning Voyageur for accelerated capital market access and strategic growth.
Alling brings over 30 years of experience in corporate banking and capital markets. As Senior Vice President & Managing Director at PNC Bank in East Brunswick, NJ, she manages a multi-billion-dollar portfolio of corporate clients, including M&A, IPOs, ESOPs, leveraged finance, and revenue optimization. Her background includes guiding private equity-backed and family-owned businesses through capital structure solutions. Previously, she served at JPMorgan Chase and Wells Fargo, and holds an MBA from the Raymond A. Mason School of Business at the College of William & Mary. She is also a Registered Investment Adviser with FINRA Series 7 & 63 licenses.
Brent Willis, Voyageur’s CEO, stated, "Her excellent track record in executing U.S. public offerings, revenue optimization, and cross-border financing complements our recent appointments. We believe that Virginia’s deep experience in M&A and capital markets will be instrumental in unlocking institutional U.S. investment, streamlining our US market entry, and ensuring robust governance as we scale our innovative barium and iodine pipeline."
The appointments underscore Voyageur's commitment to assembling a high-calibre board with proven Wall Street acumen to facilitate U.S. market expansion. Their collective experience in revenue generation, IPO execution, and regulatory compliance should support Voyageur’s commercialization efforts, including FDA approvals for its barium contrast products and scaling of its Oklahoma iodine operations.
Voyageur is a Canadian developer of pharmaceutical-grade barium and iodine for medical imaging contrast media. The company owns a 100% interest in the Frances Creek barium sulphate project, which boasts a rare and exceptional grade mineral suitable for the pharmaceutical marketplace. Voyageur aims to become the first vertically integrated company in the radiology contrast media drug market, controlling all primary input costs from raw materials to final production.
For more information, visit https://voyageurpharmaceuticals.ca.
